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Partial breast irradiation and the GEC-ESTRO trial 
 
The findings from the GEC-ESTRO randomised trial1 provide further support for partial 
breast irradiation (PBI) in women undergoing lumpectomy for breast cancer. The results 
of the TARGIT-A trial2,3 (n=3451, 2000–12) and those of the GEC-ESTRO trial1 (n=1184, 
2004–09) have more in common than suggested by the authors.1  
First, the non-inferiority margins were similar in both studies (TARGIT-A: 2·5%, GEC-
ESTRO: 3%). Second, the follow-up of the first 1222 patients in the TARGIT-A trial was 
5 years and their results were no different from those of the whole trial.2,3 Thus, the 
follow-up data were similar to the GEC-ESTRO trial1 (n=1184, median follow-up of 6·6 
years). Third, both the TARGIT-A and the GEC-ESTRO trials showed no significant 
difference in local recurrence between the two randomised groups, and both trials 
established non-inferiority between the two randomised groups. Finally, both trials 
showed a trend in improved overall survival with PBI. In the TARGIT-A trial, overall 
survival was 96·0% (95% CI 94·2–97·2) with targeted intraoperative radiotherapy 
(TARGIT) versus 94·7% (92·7–96·1) with fractionated external beam radiotherapy 
(EBRT; p=0·10); and in the GEC-ESTRO trial, it was 97·3% (96·0–98·6) with PBI versus 
95·6% (93·8–97·3) with whole breast irradiation (WBI; p=0·11).  
We did a meta-analysis of local recurrence and non-breast-cancer deaths. We used the 
data from the earliest cohort of the first 1222 patients randomly assigned to treatment 
groups in the TARGIT-A trial so the median follow-up times were similar between the 
two trials. There was no heterogeneity between the trials (p=0·52). We used Stata version 
14.0 command metan to perform the meta-analysis. Local recurrence did not differ 
between PBI and WBI, but non-breast-cancer mortality was significantly different 
between groups (figure) favouring PBI.  
The title of the Comment4 that accompanied the first TARGIT-A trial publication5 
(“Partial breast irradiation: a new standard for selected patients”) remains apt.  
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Figure	1:	Meta-analysis	of	the	outcomes	of	local	recurrence	(above)	and	non-breast-cancer	mortality	
(below).	Note	that	these	values	are	not	hazard	ratios	or	odds	ratios.	They	are	the	absolute	difference	in	
the	proportion	of	patients	who	had	an	event	in	each	of	the	randomised	arms.	The	pink	shaded	area	
shows	the	more	stringent	non-inferiority	margin	(2.5%)	for	the	TARGIT-A	trial	rather	than	the	GEC-
ESTRO	trial	(3%).		
There	was	no	heterogeneity	between	the	TARGIT-A	and	GEC-ESTRO	trial	results	(p=0.521	for	LRCB	and	
p=0.515	for	non-breast-cancer	mortality).		
The	difference	between	PBI	is	not	statistically	significant	for	local	recurrence	(p=0.12)	but	it	was	
significantly	different	for	non-breast-cancer	morality	(p=0.01).		
TARGIT-A	represents	the	earliest	cohort	of	the	first	1222	patients	in	the	TARGIT-A	trial	with	a	median	
follow	up	of	5	years.	
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